tislelizumab,cisplatin,taxane,toripalimab,nivolumab,ipilimumab
beigene,coherus,novartis,junshi,bms
#esocsm #wcgic2022 multiple ctx+io options in #escc irrespective of pdl1# rationale306:platinum+5fu or taxane plus tislelizumab mos +6.6m jupiter06:cisp+taxane plus toripalimab mos +6m cm648:cisp+5fu plus nivo mos +2.5m hard to compare trials but outlier? 
Cancer Doctor, Professor, Lifelong Learner  #GIcancer ???? @UBC @BCCancer @CCTG #Prez @CAMO #TEDxSpeaker #MedTwitter Tweets are my own